Please watch and share our PSA on psychedelic risks and adverse events. It is important to have an evidence-based perspective on the risk/benefit profile of psychedelics: https://lnkd.in/ei_fgm7B
Johns Hopkins Center for Psychedelic and Consciousness Research
Research
Baltimore, Maryland 27,469 followers
About us
Johns Hopkins Center for Psychedelic and Consciousness Research is one of the world's leading institutions researching the therapeutic benefits of psychedelics. Our research focuses on how psychedelics affect behavior, mood, cognition, brain function, and biological markers of health.
- Website
-
https://www.hopkinspsychedelic.org
External link for Johns Hopkins Center for Psychedelic and Consciousness Research
- Industry
- Research
- Company size
- 11-50 employees
- Headquarters
- Baltimore, Maryland
- Type
- Educational
- Founded
- 2019
Locations
-
Primary
5510 Nathan Shock Dr
Baltimore, Maryland 21224, US
Employees at Johns Hopkins Center for Psychedelic and Consciousness Research
-
Albert Garcia-Romeu, PhD
Associate Director of the Johns Hopkins Center for Psychedelic and Consciousness Research
-
Ceyda Sayalı
Faculty at The Johns Hopkins University School of Medicine
-
Jonathan Schettino
Licensed Psychologist, Private Practice Owner, Psychedelics Researcher, and Threat Assessment Professional
-
Nathan Sepeda
Director of Data & Analytics at the Johns Hopkins Center for Psychedelic and Consciousness Research
Updates
-
CPCR faculty Dr. Albert Garcia-Romeu, PhD discusses edible mushroom-infused products and microdosing with Slate. https://lnkd.in/dUCiZfU6
-
In an article by the New York Times, CPCR faculty Dr. Ceyda Sayalı comments on a recent publication showing individual-specific brain changes produced by psilocybin when measured by MRI: https://lnkd.in/dnNS6Yes Original publication: https://lnkd.in/etvYkk-u
This Is Literally Your Brain on Drugs
https://www.nytimes.com
-
The Economist writes about concerns with Mexico becoming a testing ground for psychedelic therapies (featuring David B. Yaden, PhD): https://lnkd.in/eACkrcMc
Mexico has become a testing ground for psychedelic therapies
economist.com
-
CPCR assistant director Dr. Albert Garcia-Romeu, PhD and colleague Dr. Marcus Hughes published a review of ethnoracial inclusion in clinical trials of psychedelics as a follow up to Michaels et al., 2018 paper. https://lnkd.in/eD8H4XGm "Underrepresentation of ethnoracial minoritized populations persists in studies examining psychedelic therapies, despite growing calls for diversity. Non-Hispanic White participants remain an over-represented majority by a large margin, though, there were greater proportions of ethnic minoritized populations included in studies since 2018, particularly in studies conducted in the USA. This indicates progress towards equity in psychedelic research, though much work is needed to inform the safety and efficacy of psychedelic treatments in the general population."
-
At the College on Problems of Drug Dependence (CPDD) 86th Annual Scientific Meeting in Montreal, Quebec, post-doc Dr. Jérémie Richard presented on differing patterns of change in alcohol and drug use behaviors among participants who had a psilocybin experience outside of a laboratory setting. The findings were indicative of improvements in these symptoms for most participants, although a small group indicated a pattern of worsening alcohol and drug use after psilocybin use. These have implications for the use of psilocybin in clinical trials, including the importance of pre-treatment screening, adequate preparation and the role of psychological support during psilocybin dosing sessions. More details are available at https://lnkd.in/eSuFXP2b
-
Dr. Sandeep Nayak was interviewed by the BBC after the FDA hearing on MDMA-assisted therapy. https://lnkd.in/gDWzzh2t
FDA advisors voted against MDMA therapy – researchers are still fighting for it
bbc.com
-
Johns Hopkins Research Study about Psychedelic Experiences Among Veterans Researchers at the Johns Hopkins Center for Psychedelic & Consciousness Research (CPCR) are seeking volunteers for a 5-10 minute survey study about psychedelic experiences among veterans. They are particularly interested in veterans with therapy/medicine experience(s) with Psilocybin and/or MDMA. To participate, please visit: https://lnkd.in/exSEDEAi
-
David B. Yaden, PhD was interviewed by the Washington Post regarding the recent FDA hearing on psychedelics. “My hope is that we will start to get a more balanced and nuanced picture of the real risks and benefits of psychedelics”. https://lnkd.in/eSmkgYp8
After FDA setback, psychedelic drugmakers distance themselves from a pioneer
washingtonpost.com